Exelixis Inc (EXEL)
21.90
-0.22
(-0.99%)
USD |
NASDAQ |
May 03, 16:00
21.90
0.00 (0.00%)
After-Hours: 20:00
Exelixis Cash from Financing (TTM): -734.69M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -734.69M |
December 31, 2023 | -546.05M |
September 30, 2023 | -341.88M |
June 30, 2023 | -124.25M |
March 31, 2023 | 4.967M |
December 31, 2022 | 0.586M |
September 30, 2022 | -15.40M |
June 30, 2022 | -16.25M |
March 31, 2022 | -11.95M |
December 31, 2021 | -14.80M |
September 30, 2021 | -15.50M |
June 30, 2021 | -16.06M |
March 31, 2021 | -29.93M |
December 31, 2020 | -25.13M |
September 30, 2020 | -9.438M |
June 30, 2020 | -2.729M |
March 31, 2020 | 9.472M |
December 31, 2019 | 12.55M |
September 30, 2019 | 14.41M |
June 30, 2019 | 14.75M |
March 31, 2019 | 15.17M |
December 31, 2018 | 9.691M |
September 30, 2018 | 10.12M |
June 30, 2018 | 9.382M |
March 31, 2018 | -98.31M |
Date | Value |
---|---|
December 31, 2017 | -169.93M |
September 30, 2017 | -153.45M |
June 30, 2017 | -157.02M |
March 31, 2017 | -54.30M |
December 31, 2016 | 15.70M |
September 30, 2016 | 6.81M |
June 30, 2016 | 156.95M |
March 31, 2016 | 150.55M |
December 31, 2015 | 152.21M |
September 30, 2015 | 145.46M |
June 30, 2015 | -4.351M |
March 31, 2015 | -0.012M |
December 31, 2014 | 65.49M |
September 30, 2014 | 65.15M |
June 30, 2014 | 64.73M |
March 31, 2014 | 64.39M |
December 31, 2013 | -11.67M |
September 30, 2013 | -11.83M |
June 30, 2013 | 404.89M |
March 31, 2013 | 404.20M |
December 31, 2012 | 478.43M |
September 30, 2012 | 478.64M |
June 30, 2012 | 64.36M |
March 31, 2012 | 71.58M |
December 31, 2011 | 187.51M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-734.69M
Minimum
Mar 2024
14.75M
Maximum
Jun 2019
-92.37M
Average
-15.10M
Median
Cash from Financing (TTM) Benchmarks
Regeneron Pharmaceuticals Inc | -1.420B |
Johnson & Johnson | -21.42B |
Merck & Co Inc | -4.81B |
Pfizer Inc | 26.07B |
Legend Biotech Corp | 791.49M |